• Users Online: 230
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 


 
 Table of Contents  
REVIEW ARTICLE
Year : 2018  |  Volume : 2  |  Issue : 1  |  Page : 1-7

Compensatory phenomena in dermatology


Department of Dermatology, Venereology and Leprosy, Shri B. M. Patil Medical College, Hospital and Research Center, BLDE University, Vijayapur, Karnataka, India

Date of Web Publication5-Jan-2018

Correspondence Address:
Arun C Inamadar
Department of Dermatology, Venereology and Leprosy, Shri B. M. Patil Medical College, Hospital and Research Center, BLDE University, Vijayapura - 586 103, Karnataka
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/CDR.CDR_26_17

Rights and Permissions
  Abstract 


Compensatory mechanisms in the human body are generally set in action when there is an absence or deficiency of an attribute to make up for the same. Such mechanisms may be intended to compensate for either the quantitative deficiency or functional impairment of an attribute performing a particular function. Frequently, in an attempt to normalize the homeostatic milieu, the compensatory mechanisms may work more than necessary producing undesired effects as well. In this review, we describe some of such compensatory phenomena in relation to clinical, immunological, pathological, and few other aspects of dermatology, as well as such phenomena characterizing some of the dermatotherapeutics.

Keywords: Compensatory hyperhidrosis, desmoglein compensation, extramedullary hematopoiesis


How to cite this article:
Adya KA, Inamadar AC, Palit A. Compensatory phenomena in dermatology. Clin Dermatol Rev 2018;2:1-7

How to cite this URL:
Adya KA, Inamadar AC, Palit A. Compensatory phenomena in dermatology. Clin Dermatol Rev [serial online] 2018 [cited 2018 Oct 22];2:1-7. Available from: http://www.cdriadvlkn.org/text.asp?2018/2/1/1/222272




  Introduction Top


Compensatory phenomena can be described as the mechanisms in the body which compensate for the diminished or complete lack of a particular attribute that normally performs a function with the intent to maintain the normal homeostatic milieu. Such phenomena can be mediated by the mechanisms that over-function to compensate for the loss or diminished function of a part of the same (e.g., compensatory hyperhidrosis) or can be mediated by other but related mechanisms (e.g., chronic granulomatous disease). However, such overactivity may produce undesired manifestations and/or be responsible for the typical clinicopathological findings associated with a certain disorder. [Table 1] summarizes some of the compensatory phenomena in different aspects dermatology discussed in this review.
Table 1: Compensatory phenomena in dermatology

Click here to view



  Immunological Compensatory Phenomena Top


Desmoglein compensation in pemphigus

Desmogleins (Dsgs) are the principal components of the desmosomes – the intercellular adhesion molecules which are the predominant antigenic determinants in the pemphigus group of immunobullous disorders. The Dsg 1 and Dsg 3 are the major Dsg isoforms whose expression patterns in the epidermis of the skin and the mucosa differ. The Dsg 1 is expressed throughout the epidermis of the skin; more so in the subcorneal region, whereas Dsg 3 is expressed weakly and only in the basal and suprabasal regions. Although both the Dsg 1 and Dsg 3 are expressed throughout the mucosal epidermis, the expression of Dsg 1 is quantitatively much less. These variable expression patterns of Dsgs in skin and mucosal epidermis account for the different clinical patterns of blistering in different forms of pemphigus.

In the mucosal-dominant pemphigus vulgaris, antibodies are produced essentially against Dsg 3 and the increased expression of the Dsg 1 compensates for the loss of Dsg 3 in the skin preventing blister formation. Mucocutaneous pemphigus vulgaris is characterized by both skin and mucosal lesion as antibodies are produced against both the Dsg 1 and Dsg 3. However, despite the presence of anti-Dsg 1 antibodies, the epidermal split in the skin is only suprabasal. This is possibly due to weaker intercellular adhesion in this region due to lesser desmosomes and better access to the antibodies to this region traversing through the dermal vessels. Pemphigus foliaceous is characterized by only anti-Dsg 1 antibody production and the compensation for the loss of Dsg 1 in the mucosa by the intensely expressed Dsg 3 prevents intraoral lesions. In the skin too, the blisters are only subcorneal as the Dsg 3 in lower epidermis (though minimal) compensates for the loss of Dsg 1.[1]

Chronic granulomatous disease

Chronic granulomatous disease is a rare primary immunodeficiency disorder characterized by deficient mechanisms to kill the phagocytosed microbes. This defect occurs due to the mutations in one of the genes encoding the subunits of the superoxide-generating phagocyte nicotinamide adenine dinucleotide phosphate oxidase enzyme complex responsible for the microbicidal respiratory burst. Among the four forms (one X-linked recessive and three autosomal recessive), the X-linked recessive form of the disease is the most common and the most severe form characterized by complete absence of the enzyme activity due to mutation in the cytochrome B-245 beta chain gene.

In the absence of superoxide production within the phagocytic vacuole, the activation of the proteases by them leading to killing of the organisms does not take place. As a result of this immunological deficiency, several compensatory mechanisms act in an attempt to keep the infection confined. These include granuloma formation, overactivity of humoral immunity, and an exaggerated cellular inflammatory reaction which account for the clinical manifestations such as suppurative lymphadenitis, pneumonitis, inflammatory bowel disease, and the characteristic granulomata of the gastrointestinal tract, lymph nodes, liver, spleen, and lungs. Mucocutaneous involvement occurs in 60%–70% of the cases and the common manifestations include gingivostomatitis, periorificial seborrheic dermatitis-like rash, recurrent cutaneous staphylococcal abscess, and lupus erythematosus-like rash.[2],[3],[4]


  Endocrinological Compensatory Phenomena Top


Addison's disease (primary adrenal insufficiency)

The pathognomonic diffuse noninflammatory cutaneous hyperpigmentation of primary adrenal insufficiency is attributed to compensatory overproduction of adrenocorticotropic hormone (ACTH) by the pituitary to normalize the reduced adrenal cortisol and mineralocorticoid secretion. The excess circulating ACTH exerts a stimulatory effect on the melanocytes by binding to the melanocortin 1 receptors expressed on them. Although generally diffuse, the hyperpigmentation of Addison's disease preferentially involves the sun-exposed and pressure-bearing areas, nails (longitudinal melanonychia), palmar creases, and any existing scars. Darkening of the normally pigmented structures (e.g., nipples and areola, flexures, perineum, and perianal regions) and of the pigmented lesions (e.g., melanocytic nevi and café-au-lait macules) is noted as well.[5],[6]

Hyperandrogenism-insulin resistance-acanthosis Nigricans syndrome

The hyperandrogenism-insulin resistance-acanthosis nigricans (HAIR-AN) syndrome is one of the inherited insulin resistance syndromes characterized by insulin receptor and/or postreceptor pathway defects. The insulin resistance in HAIR-AN syndrome is quite severe that results in a compensatory hyperinsulinemia which, in early stages of the disease, is able to maintain a normal fasting blood glucose. The hyperinsulinemia also increases the steroidogenic action of luteinizing hormone resulting in hyperandrogenism. The acanthosis nigricans and virilization due to such intense hyperinsulinemia and hyperandrogenism, respectively, are hence quite severe, with the latter often raising the suspicion of an androgen-secreting tumor until proven otherwise by radiological and endocrinological assays. The patients are also at a greater risk of developing type 2 diabetes mellitus, hypertension, and cardiovascular disorders.[7],[8]

Hyperparathyroidism in Vitamin D-dependent rickets

Vitamin D-dependent rickets (VDDR) type I and II are rare autosomal recessive disorders associated with impaired calcium and phosphate absorption resulting in hypocalcemia and early onset rickets. Type I VDDR is characterized by deficiency of 1α-hydroxylase enzyme and is associated with low serum levels of calcitriol, whereas in type II VDDR, there is defect in the Vitamin D receptor signaling pathways which is associated with normal or even markedly elevated serum calcitriol.

To compensate for the hypocalcemia in either, there is secondary hyperparathyroidism with markedly elevated serum parathormone leading to increased bone resorption evidenced by increased serum alkaline phosphatase and serum cross-linked type I collagen carboxy-terminal telopeptide levels and increased urinary excretion of cross-linked type I collagen N-telopeptides. This mechanism, however, becomes progressively inadequate in untreated and the patients develop the characteristic rachitic manifestations. The type II VDDR is dermatologically important as generalized early-onset (within first few months of life) noncicatricial alopecia seen in this disorder resembles atrichia congenita. Although the latter is a distinct entity, infants with such presentation must be evaluated radiologically and biochemically for VDDR.[9],[10],[11]


  Compensatory Metabolic Phenomena Top


Hypermetabolism in erythroderma

Erythroderma (any inflammatory skin disorder involving >90% of the body surface area) is associated with many internal derangements, most notably the deranged thermoregulation. It occurs due to excessive heat loss through the skin attributed to increased cutaneous circulation and to impaired cutaneous thermoregulatory barrier. Patients with chronic erythroderma can develop cachexia due to hypermetabolism occurring as a compensatory mechanism to counter the chronic and excessive heat loss and to maintain the core body temperature. This hypermetabolism is unassociated with increased thyroid activity.[12],[13]

Congenital lipodystrophies

Congenital lipodystrophies are a heterogeneous group of inherited syndromes characterized by variable absence of adipose tissue in the body. Conventionally, these disorders are classified based on the degree of adipose tissue deficiency as generalized, generalized but partial, and localized lipodystrophies. The congenital generalized lipodystrophy (Berardinelli-Seip syndrome) is characterized by universal loss of adipose tissue often at birth. In the inherited partial lipodystrophies, the lipoatrophy commences at about puberty or early adulthood and is characterized by significant loss of subcutaneous fat in the limbs and gluteal region associated with a compensatory excessive accumulation of fat involving the face, neck, back, and trunk, often in a Cushingoid manner, resulting in an overall increased body adipose tissue in some cases.

In either of these inherited lipodystrophies, there is a compensatory upregulation of the visceral fat increasing the risk of metabolic syndrome. The metabolically active visceral fat produces more tumor necrosis factor alpha and interleukin 6 and less adiponectin which lead to insulin resistance. The degree of insulin resistance is variable depending on the extent of fat loss which leads to compensatory hyperinsulinemia and its consequences such as type II diabetes mellitus, hyperlipidemia, acanthosis nigricans, and virilization in females (as described under HAIR-AN syndrome).[14],[15]


  Compensatory Hyperhidrosis Top


Compensatory hyperhidrosis is an example for the functionally normal anatomical structures that overwork to make up for the loss/inactivity of a part of the same. The loss may be a quantitative reduction of sweat glands or their functional inactivity.[16] Compensatory hyperhidrosis can occur at a site distant from the affected area and is graded as mild, moderate, and intense based on the volume of sweat production, discomfort caused to the patient, and the resultant social embarrassment.[17] The causes of quantitative and functional deficiency of the sweat glands associated with compensatory hyperhidrosis are outlined in [Table 2].
Table 2: Causes of compensatory hyperhidrosis

Click here to view


The most common cause of compensatory hyperhidrosis encountered in clinical practice is following sympathectomy for palmoplantar or axillary hyperhidrosis. The trunk is the most common site of increased sweating following sympathectomy. The pathomechanism proposed in this condition is the lack of negative feedback to the hypothalamus due to sectioning of the afferent neuronal pathways.[17] In the Ross syndrome, the hypo- or anhidrosis (accompanied by tonic dilated pupil and areflexia) is segmental, progressive, and associated with compensatory contralateral segmental hyperhidrosis. The exact pathophysiology of this disorder is unknown. The hypo- or anhidrosis is due to damage to the postganglionic sympathetic innervations of the sweat glands. The compensatory hyperhidrosis is believed to be due to the overactivity of the sweat glands whose innervations are still intact but reduces overtime, and complete anhidrosis eventually ensues.[19],[20] Harlequin syndrome, characterized by unilateral anhidrosis and reduced flushing due to damaged efferent sympathetic nerves, also demonstrates compensatory hyperhidrosis usually associated with excessive flushing contralateral to the affected segment. Spinal injuries also can produce segmental hypohidrosis with contralateral compensatory hyperhidrosis.[21]

The most common acquired disorders associated with autonomic dysfunction are diabetes and leprosy. Diabetics may develop hypohidrosis of the extremities due to microangiopathic and neuropathic complications of the disease, which is associated with two types of compensatory hyperhidrosis – a thermally induced hyperhidrosis of the upper half of the body and a compensatory gustatory hyperhidrosis.[18],[21] In untreated long-standing lepromatous leprosy, the peripheral anesthesia is associated with hypo- or anhidrosis due to involvement of autonomic nervous system. This hypo- or anhidrosis is often accompanied by compensatory hyperhidrosis of the trunk and axillae.[22] A similar pattern of compensatory hyperhidrosis due to decreased postganglionic stimulation of sweat glands of palms is seen Parkinson's disease.[23] Other primary chronic forms of dysautonomias-like  Bradbury-Eggleston syndrome More Details (pure autonomic failure), multiple system atrophy, and Parkinson's disease with orthostatic hypotension are also associated with diminished sweating and compensatory asymmetrical hyperhidrosis.[24]

Examples for quantitative deficiency of sweat glands associated with compensatory hyperhidrosis include miliaria,[16] congenital erosive and vesicular dermatosis,[25] and following local surgery for axillary hyperhidrosis.[18],[26] Although botulinum toxin therapy has been a successful modality for gustatory, axillary, palmoplantar, and for compensatory hyperhidrosis following sympathectomy,[27] it has, however, also been reported to produce compensatory nonaxillary hyperhidrosis when employed in the treatment of axillary hyperhidrosis.[28]


  Cutaneous Extramedullary Hematopoiesis Top


Extramedullary hematopoiesis is a compensatory phenomenon that coexists with disorders associated with compromised normal bone marrow hematopoietic function. The most common associations include myeloproliferative disorders and the hemoglobinopathies. The most common sites of extramedullary hematopoiesis are liver, spleen, and paraspinal regions.[29] Extramedullary hematopoiesis in the skin is rare and has been described with myelofibrosis. The cutaneous lesions have varied morphology and clinically manifest as erythematous firm papules, infiltrated plaques, nodules, ulcers, or angiomatous nodules. Histology demonstrates precursor hematopoietic cells.[30] Cutaneous extramedullary hematopoiesis represents the ability of the skin to resume dermal hematopoiesis when the need arises which otherwise is an in utero feature that normally ceases before birth.[31]

Continuation or persistence of dermal erythropoiesis in the neonatal period was first described with congenital rubella. However, several other infections, hematologic disorders and malignancies, and certain other disorders also are associated with this phenomenon [Table 3]. Clinically, persistent dermal erythropoiesis in these settings manifests as congenital multiple, diffuse, rubbery papules and nodules exhibiting a characteristic bluish or magenta color – “the blue-berry muffin baby” [Figure 1]. These lesions normally regress into faint brownish macules in a few weeks after birth.[32] Although a compensatory demand, deficient replacement, or dysfunction of cellular elements of blood have been speculated, the exact cause resulting in persistent dermal erythropoiesis is unclear.[33]
Figure 1: “Blueberry muffin” rash in a newborn with congenital rubella

Click here to view
Table 3: Disorders associated with cutaneous extramedullary hematopoiesis

Click here to view



  Compensatory Phenomena in Dermatopathology Top


Incontinentia pigmenti (Bloch-Sulzberger syndrome)

Incontinentia pigmenti is an X-linked dominant disorder due to mutation in the nuclear factor-κβ essential modulator (NEMO) gene that normally prevents tumor necrosis factor-alpha-induced keratinocyte apoptosis. Hence, the first stage of the disease is characterized by inflammatory and vesicular lesions due to apoptosis of the NEMO-deficient cells along the Blaschko's lines. The verrucous (second) stage is the result of replacement of the NEMO-deficient cells with keratinocytes expressing the normal allele and their compensatory hyperproliferation. The keratinocyte damage is associated with melanin incontinence into the upper dermis that produces the conspicuous linear streaky hyperpigmentation of the skin in the third stage. The pigmentation gradually fades away and may be replaced by hypopigmentation (the fourth stage).[5]

Congenital ichthyosis

The congenital ichthyosis is a group of disorders inherited due to mutations in the genes encoding the proteins necessary to essentially maintain a homeostasis between the epidermal turnover and desquamation rates, thereby maintaining the integrity and barrier properties of the epidermis. The various clinical manifestations of different types of congenital ichthyosis are basically results of compensatory mechanisms in an attempt to normalize the epidermal structural and functional properties. Increased epidermal lipid synthesis and epidermal hyperproliferation are the notable among such mechanisms. The latter is typically exemplified in harlequin ichthyosis, lamellar ichthyosis (especially in patients with adenosine triphosphate binding cassette, subfamily A, member 12 gene mutation), and keratinopathic ichthyoses. The compensatory epidermal hyperproliferation is not only intended to normalize its barrier properties but also as a protective effect against blistering due to external noxious stimuli.[34],[35],[36],[37]

Psoriasis

In psoriasis, the normal homeostasis between the epidermal turnover, maturation, and desquamation is disturbed and there is an increase in the ratio of the proliferating epidermal keratinocytes to the resting ones. As a result, a substantial increase in the quantum of the germinative basal layer occurs and to accommodate the same, there is enlargement and elongation of the rete pegs. This is associated with compensatory elongation of the dermal papillae as well, thereby increasing the dermoepidermal interface and physiochemical interactions.[38],[39]

Darier's disease

In Darier's disease, the focal suprabasal clefting due to acantholysis and overlying dyskeratosis of the keratinocytes are the pathognomonic histopathological features. As a compensatory mechanism to this abnormality, the basal keratinocytes proliferate and project into the suprabasal cleft as “villi” which are also an important diagnostic feature.[38],[40]

Hair follicle cycle and wound healing

Animal studies have demonstrated that wounds heal faster in hair bearing areas compared to the ones on non-hairy areas. Further, wounds heal faster when the hairs in the wounded area are in anagen phase as opposed to telogen phase. This phenomenon is attributed to the contribution of hair follicle stem cells in accelerating the onset of wound reepithelialization, which under normal circumstances are not involved in maintenance of epithelial homeostasis. After wounding, the stem cells in the hair follicles migrate to the epidermis and assist reepithelialization. In the anagen phase, both the interfollicular as well as outer root sheath epithelia proliferate rapidly at the onset of wound reepithelialization which effect faster healing of the wound. This proliferative process begins later in telogen phase probably to compensate for the initial slower rate of healing and effects a “catch-up” complete reepithelialization. The role of anagen hair follicles in hastening the wound healing is not just limited to their harboring of stem cells but the alterations in the local microenvironment during this phase of hair cycle (increased expression of late terminal differentiation markers of epithelium, decreased inflammation, increased angiogenesis, and accelerated matrix deposition) also promote faster wound healing.[41],[42],[43] These observations, however, still need to be proven in humans.


  Compensatory Phenomena in Relation to Common Dermatotherapeutics Top


Doxycycline

Doxycycline shares several metabolic properties with the other tetracyclines. However, a feature unique to this drug is the non-accumulation in body tissues in the presence of renal failure even though the renal excretion accounts for up to 50% of the administered drug. This phenomenon is due to the fact that, apart from the kidneys, the drug is also excreted through hepatic and gastrointestinal routes. In the presence of renal failure, there is a compensatory increase in the gastrointestinal secretion of the drug and hence, although the urinary concentration and total urinary excretion of doxycycline are significantly diminished, the renal tissue concentration is normal. Therefore, doxycycline is considered to be a safe antibiotic even in advanced renal failure.[44],[45],[46] However, administration of the drug in renal failure with concomitant impairment in the extrarenal excretory pathways can deteriorate the renal condition.[47]

“Catch-up” growth on discontinuation of steroids

Linear growth retardation in children receiving long-term corticosteroids is a well-known entity which one should be mindful of while treating. However, the dose of corticosteroids necessary for such growth suppression in much greater than the physiological dose and also there is a compensatory spurt in the linear growth on discontinuation of steroids. This “catch-up” growth is attributed to factors intrinsic to the epiphyseal growth plate. The antiproliferative effects of corticosteroids slow down the senescence of the growth plate chondrocytes. Once the steroids are discontinued, the epiphyseal plate resumes its proliferative function and compensatory linear growth spurt occurs. This compensatory growth may occur at a much accelerated rate and may even extend beyond expected for that age as the epiphyseal growth plate would not have “aged” as far as it normally should have.[48],[49],[50] However, administration of glucocorticoids before the age of 2 years, and just before puberty may not be associated with this compensatory “catch-up” linear growth phenomenon.[51]


  Conclusion Top


A preliminary knowledge of such phenomena in relation to different aspects of dermatology is helpful for the clinicians as well as learners to correlate the clinical findings, ascertain the diagnosis, and to preempt certain events following a treatment which would be helpful in their prevention and management.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Siddiqui S, Haroon MA, Hasan S, Khalid A. To determine desmoglein compensation theory: An explanation for early appearance of oral lesions as compared to skin lesions in pemphigus vulgaris. Int Arch Biomed Clin Res 2016;2:13-7.  Back to cited text no. 1
    
2.
Nowicki RJ. Chronic Granulomatous Disease. Available from: http://www.emedicine.medscape.com/article/1116022-overview#a4. [Last accessed on 2017 May 20].  Back to cited text no. 2
    
3.
James WD, Berger TG, Elston DM, Neuhaus IM. Atopic dermatitis, eczema and non-infectious immunodeficiency disorders. In: James WD, Berger TG, Elston DM, Neuhaus IM, editors. Andrews' Diseases of the Skin Clinical Dermatology. 12th ed. Philadelphia: Elsevier Saunders; 2016. p. 62-89.  Back to cited text no. 3
    
4.
Schaffer JV, Paller AS. Primary immunodeficiencies. In: Bolognia JL, Jorizzo JL, Rapini RP, editors. Dermatology. 2nd ed. London: Elsevier; 2008. p. 801-23.  Back to cited text no. 4
    
5.
Lapeere H, Boone B, De Schepper S, Verhaeghe E, Van Gele M. Lambert J, et al. Hypomelanoses and hypermelanoses. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K, editors. Fitzpatrick's Dermatology in General Medicine. 8th ed. New York: The McGraw-Hill Companies; 2012. p. 804-26.  Back to cited text no. 5
    
6.
Adya KA, Inamadar AC. Systemic disorders with cutaneous pigmentary alterations. In: Lahiri K, Chatterjee M, Sarkar R, editors. Pigmentary Disorders a Comprehensive Compendium. 1st ed. New Delhi: Jaypee Brothers Medical Publishers; 2014. p. 22-39.  Back to cited text no. 6
    
7.
Practice Committee of the American Society for Reproductive Medicine. The evaluation and treatment of androgen excess. Fertil Steril 2006;86:S241-7.  Back to cited text no. 7
[PUBMED]    
8.
Dédjan AH, Chadli A, El Aziz S, Farouqi A. Hyperandrogenism-insulin resistance-acanthosis Nigricans syndrome. Case Rep Endocrinol 2015;2015:193097.  Back to cited text no. 8
    
9.
Feldman D, Malloy PJ. Mutations in the Vitamin D receptor and hereditary Vitamin D-resistant rickets. Bonekey Rep 2014;3:510.  Back to cited text no. 9
    
10.
Baroncelli GI, Bertelloni S, Ceccarelli C, Amato V, Saggese G. Bone turnover in children with Vitamin D deficiency rickets before and during treatment. Acta Paediatr 2000;89:513-8.  Back to cited text no. 10
[PUBMED]    
11.
Melinda J, Albert CY. Cutaneous changes in nutritional diseases. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K, editors. Fitzpatrick's Dermatology in General Medicine. 8th ed. New York: The McGraw-Hill Companies; 2012. p. 1499-525.  Back to cited text no. 11
    
12.
Sehgal VN, Karadag AS, Srivastava G. Erythroderma/exfoliative dermatitis. In: Wolf R, Parish LC, Parish JL, editors. Emergency Dermatology. 2nd ed. Boca Raton: CRC Press Taylor & Francis Group; 2017. p. 193-209.  Back to cited text no. 12
    
13.
Sterry E, Steinhoff M. Erythroderma. In: Bolognia JL, Jorizzo JL, Schaffer JV, editors. Dermatology. 3rd ed. London: Elsevier; 2012. p. 171-81.  Back to cited text no. 13
    
14.
Huang-Doran I, Sleigh A, Rochford JJ, O'Rahilly S, Savage DB. Lipodystrophy: Metabolic insights from a rare disorder. J Endocrinol 2010;207:245-55.  Back to cited text no. 14
    
15.
Mediana-Gomez G, Lelliott C, Vidal-Puig AJ. Genetically modified mouse models of insulin resistance. In: Kumar S, O'Rahilly S, editors. Insulin Resistance: Insulin Actions and its Disturbances in Disease. 1st ed. West Sussex: John Wiley and Sons Ltd.; 2005. p. 133-53.  Back to cited text no. 15
    
16.
Miller JL. Diseases of the eccrine and apocrine sweat glands. In: Bolognia JL, Jorizzo JL, Schaffer JV editors. Dermatology. 3rd ed. London: Elsevier; 2012. p. 587-602.  Back to cited text no. 16
    
17.
Lyra Rde M, Campos JR, Kang DW, Loureiro Mde P, Furian MB, Costa MG, et al. Guidelines for the prevention, diagnosis and treatment of compensatory hyperhidrosis. J Bras Pneumol 2008;34:967-77.  Back to cited text no. 17
[PUBMED]    
18.
Rezende RM, Luz FB. Surgical treatment of axillary hyperhidrosis by suction-curettage of sweat glands. An Bras Dermatol 2014;89:940-54.  Back to cited text no. 18
[PUBMED]    
19.
Baran A, Balbaba M, Demir CF, Ozdemir HH. A case of Ross syndrome presented with Horner and chronic cough. J Neurosci Rural Pract 2014;5:394-7.  Back to cited text no. 19
[PUBMED]  [Full text]  
20.
Metta AK, Athanikar SB, Ramachandra S, Mohammad S. Ross syndrome. Indian J Dermatol Venereol Leprol 2009;75:414-6.  Back to cited text no. 20
[PUBMED]  [Full text]  
21.
Schlereth T, Dieterich M, Birklein F. Hyperhidrosis – Causes and treatment of enhanced sweating. Dtsch Arztebl Int 2009;106:32-7.  Back to cited text no. 21
[PUBMED]    
22.
Kumar B, Dogra S. Leprosy. In: Bope ET, Kellerman RD, editors. Con's Current Therapy. 1st ed. Philadelphia: Elsevier Saunders; 2013. p. 111-17.  Back to cited text no. 22
    
23.
Schestatsky P, Valls-Solé J, Ehlers JA, Rieder CR, Gomes I. Hyperhidrosis in Parkinson's disease. Mov Disord 2006;21:1744-8.  Back to cited text no. 23
    
24.
Gil-Diaz A, Conde-Martel A, Betancor-Leon P. A 69-year-old man with excessive sweating of the right hemithorax. BMJ Case Rep 2011;2011. pii: bcr0320113970. doi: 10.1136/bcr. 03.2011.3970.  Back to cited text no. 24
    
25.
Paller AS, Mancini A. Cutaneous disorders of the newborn. In: Paller AS, Mancini A, editors. Hurwitz Clinical Pediatric Dermatology. 4th ed. Edinburgh: Elsevier Saunders; 2011. p. 10-36.  Back to cited text no. 25
    
26.
Heidemann E, Licht PB. A comparative study of thoracoscopic sympathicotomy versus local surgical treatment for axillary hyperhidrosis. Ann Thorac Surg 2013;95:264-8.  Back to cited text no. 26
[PUBMED]    
27.
Heckmann M, Ceballos-Baumann AO, Plewig G, Hyperhidrosis Study Group. Botulinum toxin A for axillary hyperhidrosis (excessive sweating). N Engl J Med 2001;344:488-93.  Back to cited text no. 27
    
28.
Naumann M, Lowe NJ. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: Randomised, parallel group, double blind, placebo controlled trial. BMJ 2001;323:596-9.  Back to cited text no. 28
[PUBMED]    
29.
Lee KJ, Boswell WD. Extramedullary Hematopoiesis. Available from: http://www.medscape.com/viewarticle/514632_4. [Last accessed on 2017 Jun 01].  Back to cited text no. 29
    
30.
Corella F, Barnadas MA, Bordes R, Curell R, Espinosa I, Vergara C, et al. A case of cutaneous extramedullary hematopoiesis associated with idiopathic myelofibrosis. Actas Dermosifiliogr 2008;99:297-300.  Back to cited text no. 30
[PUBMED]    
31.
Kuo T, Uhlemann J, Reinhard EH. Cutaneous extramedullary hematopoiesis. Arch Dermatol 1976;112:1302-3.  Back to cited text no. 31
[PUBMED]    
32.
Paige DG. Dermatoses of the neonate. In: Griffiths CE, Barker J, Bleiker T, Chalmers R, Creamer D, editors. Rook's Textbook of Dermatology. 9th ed. Oxford: Wiley-Blackwell; 2016. p. 116.1-116.30.  Back to cited text no. 32
    
33.
Hödl S, Auböck L, Reiterer F, Soyer HP, Müller WD. Blueberry muffin baby: The pathogenesis of cutaneous extramedullary hematopoiesis. Hautarzt 2001;52:1035-42.  Back to cited text no. 33
    
34.
Paller AS, Mancini A. Hereditary disorders of cornification. In: Paller AS, Mancini A, editors. Hurwitz Clinical Pediatric Dermatology. 4th ed. Edinburgh: Elsevier Saunders; 2011. p. 92-114.  Back to cited text no. 34
    
35.
Segre JA. Epidermal barrier formation and recovery in skin disorders. J Clin Invest 2006;116:1150-8.  Back to cited text no. 35
[PUBMED]    
36.
Zuo Y, Zhuang DZ, Han R, Isaac G, Tobin JJ, McKee M, et al. ABCA12 maintains the epidermal lipid permeability barrier by facilitating formation of ceramide linoleic esters. J Biol Chem 2008;283:36624-35.  Back to cited text no. 36
[PUBMED]    
37.
Elias PM, Williams ML, Holleran WM, Jiang YJ, Schmuth M. Pathogenesis of permeability barrier abnormalities in the ichthyoses: Inherited disorders of lipid metabolism. J Lipid Res 2008;49:697-714.  Back to cited text no. 37
[PUBMED]    
38.
Mihm MC Jr., Kibbi AG, Murphy GF, Wolff K. Basic pathologic reactions of the skin. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K, editors. Fitzpatrick's Dermatology in General Medicine. 8th ed. New York. The McGraw-Hill Companies; 2012. p. 42-57.  Back to cited text no. 38
    
39.
Mc Donald C. Use of methotrexate in the treatment of psoriasis and other dermatological disorders. In: Cronstein MB, Bertino JR, editors. Methotrexate. 1st ed. Basel: Springer Basel AG; 2000. p. 109-24.  Back to cited text no. 39
    
40.
Chung J, Kim JY, Gye J, Namkoong S, Hong SP, Park BC, et al. A case of familial Comedonal Darier's disease. Ann Dermatol 2011;23:S398-401.  Back to cited text no. 40
[PUBMED]    
41.
Stojadinovic O, Ito M, Tomic-Canic M. Hair cycling and wound healing: To pluck or not to pluck? J Invest Dermatol 2011;131:292-4.  Back to cited text no. 41
[PUBMED]    
42.
Ansell DM, Kloepper JE, Thomason HA, Paus R, Hardman MJ. Exploring the “hair growth-wound healing connection”: Anagen phase promotes wound re-epithelialization. J Invest Dermatol 2011;131:518-28.  Back to cited text no. 42
[PUBMED]    
43.
Ito M, Cotsarelis G. Is the hair follicle necessary for normal wound healing? J Invest Dermatol 2008;128:1059-61.  Back to cited text no. 43
[PUBMED]    
44.
Riond JL, Riviere JE. Pharmacology and toxicology of doxycycline. Vet Hum Toxicol 1988;30:431-43.  Back to cited text no. 44
[PUBMED]    
45.
Whelton A, Schach von Wittenau M, Twomey TM, Walker WG, Bianchine JR. Doxycycline pharmacokinetics in the absence of renal function. Kidney Int 1974;5:365-71.  Back to cited text no. 45
[PUBMED]    
46.
Stenbæk Ø, Myhre E, Peter Berdal B. Doxycycline in renal failure. Curr Med Res Opin 1975;3:24-30.  Back to cited text no. 46
    
47.
Orr LH Jr., Rudisill E Jr., Brodkin R, Hamilton RW. Exacerbation of renal failure associated with doxycycline. Arch Intern Med 1978;138:793-4.  Back to cited text no. 47
    
48.
Donatti TL, Koch VH, Takayama L, Pereira RM. Effects of glucocorticoids on growth and bone mineralization. J Pediatr (Rio J) 2011;87:4-12.  Back to cited text no. 48
[PUBMED]    
49.
Baron J, Klein KO, Colli MJ, Yanovski JA, Novosad JA, Bacher JD, et al. Catch-up growth after glucocorticoid excess: A mechanism intrinsic to the growth plate. Endocrinology 1994;135:1367-71.  Back to cited text no. 49
[PUBMED]    
50.
Gafni RI, Weise M, Robrecht DT, Meyers JL, Barnes KM, De-Levi S, et al. Catch-up growth is associated with delayed senescence of the growth plate in rabbits. Pediatr Res 2001;50:618-23.  Back to cited text no. 50
[PUBMED]    
51.
Jackson SM, Nesbitt LT Jr. Glucocorticosteroids. In: Bolognia JL, Jorizzo JL, Schaffer JV, editors. Dermatology. 3rd ed. London: Elsevier; 2012. p. 2075-88.  Back to cited text no. 51
    


    Figures

  [Figure 1]
 
 
    Tables

  [Table 1], [Table 2], [Table 3]



 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
Abstract
Introduction
Immunological Co...
Endocrinological...
Compensatory Met...
Compensatory Hyp...
Cutaneous Extram...
Compensatory Phe...
Compensatory Phe...
Conclusion
References
Article Figures
Article Tables

 Article Access Statistics
    Viewed1047    
    Printed112    
    Emailed0    
    PDF Downloaded210    
    Comments [Add]    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]